Welcome to our dedicated page for Evaxion Biotech A/S news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S stock.
Evaxion Biotech A/S (EVAX) is a clinical-stage biotechnology company leveraging proprietary AI platforms to advance immunotherapies for cancer and infectious diseases. This page serves as the definitive source for verified corporate announcements, research milestones, and strategic developments.
Investors and industry observers will find timely updates on clinical trial progress, regulatory filings, and technology innovations. Our curated collection includes press releases on AI-driven drug discovery, partnership announcements, and financial reports, all organized for efficient tracking of the company's trajectory.
Key content areas include updates from Evaxion's PIONEER and EDEN platform pipelines, oncology vaccine developments, and infectious disease research breakthroughs. The repository is maintained to reflect the company's evolving position at the intersection of artificial intelligence and immunotherapy.
Bookmark this page for streamlined access to Evaxion's official communications. Check regularly for new developments in personalized cancer vaccines and AI-optimized antigen discovery.
Evaxion Biotech A/S (NASDAQ: EVAX) announced successful production of personalized cancer immunotherapies for all patients in its Phase 1/2a trial of EVX-02 for adjuvant melanoma. The team confirmed the feasibility of its complex production chain within a critical timeframe. The trial, involving 16 fully resected patients in Australia, aims to prevent disease relapse using AI-driven, DNA-based immunotherapies. This achievement strengthens Evaxion's capabilities for larger trials exploring clinical benefits, bolstering investor confidence in its AI-immunology platform and the future of personalized cancer treatment.
Evaxion Biotech A/S (NASDAQ: EVAX) will present its first-quarter 2022 financial results on May 11 at 8:30 a.m. EDT. For those wishing to join the conference call, the US dial-in number is 1-877-407-0792 and the international number is 1-201-689-8263, using Conference ID 13729241. The event can also be accessed via a webcast on Evaxion's website. Evaxion is a clinical-stage biotechnology company focused on AI-driven immunotherapies for treating cancer and infectious diseases. Their pipeline includes three patient-specific cancer immunotherapies.
Evaxion Biotech and Personalis announced a collaboration utilizing the ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy of Evaxion's cancer immunotherapy EVX-01. The trial will study the combination of EVX-01 with KEYTRUDA in metastatic melanoma patients. Evaxion's AI tool PIONEER is expected to enhance treatment precision by targeting significant cancer mutations. The partnership aims to improve patient outcomes and advance companion diagnostics. Both companies leverage advanced AI and genomic technologies to boost cancer therapy development.
Evaxion Biotech (NASDAQ: EVAX) announced a KOL webinar focusing on personalized cancer immunotherapies, scheduled for April 12, 2022, at 12:30 pm ET. Featured speakers include KOLs Jeffrey S. Weber, MD, PhD, and Patrick Ott, MD, PhD, who will discuss melanoma treatment options and the potential of AI-driven therapeutic strategies. Evaxion's management will also provide company updates during the session. This event highlights the company's commitment to advancing personalized medicine in oncology and engaging with key experts in the field.
Evaxion Biotech reported a successful follow-on public offering (FPO) of 3,942,856 ordinary shares, raising $24.9 million in net proceeds. The company announced a critical collaboration with Merck to evaluate its immunotherapy EVX-01 alongside KEYTRUDA® in a Phase 2b clinical trial for metastatic melanoma. As of December 31, 2021, Evaxion had cash and cash equivalents totaling $32.2 million, ensuring operational funding for at least 12 months. The firm has also received Australian clearance for its clinical trial and achieved significant clinical milestones, underlining its commitment to innovation in cancer treatment.
Evaxion Biotech A/S (NASDAQ: EVAX) announced key management additions: Bo Karmark as Chief Financial Officer and Jesper Nyegaard Nissen as Chief Operating Officer. Both bring over 25 years of experience in the biotech and pharmaceutical sectors, expected to enhance Evaxion's growth and clinical development efforts. CEO Lars Wegner expressed confidence in their capabilities to advance the company’s promising pipeline of AI-powered immunotherapies for cancer and infectious diseases. The company's strategy aims to leverage AI for effective drug discovery.
Evaxion Biotech A/S (NASDAQ: EVAX) has completed recruitment for its Phase 1/2a clinical trial of EVX-02, targeting adjuvant melanoma patients. The Company aims to prevent tumor relapse post-surgery. Encouraging preliminary findings indicate the treatment is well-tolerated, with no serious side effects reported. The next step is a dedicated Phase 2b trial, expected to begin following the finalization of recruitment. Final data from the current trial will be announced in Q2 2023, earlier than anticipated, with milestones including regulatory filings in H1 2022.
Evaxion Biotech A/S (NASDAQ: EVAX) announced the publication of a paper on its personalized cancer immunotherapy EVX-01 aimed at metastatic melanoma, published in OncoImmunology. The Phase 1/2a trial results indicate that EVX-01 is safe and shows early signs of antitumor activity when combined with standard anti-PD-1 treatment, supported by the company's PIONEER AI technology. The upcoming Phase 2b trial, in collaboration with Merck, is set to begin in Q2 2022, focusing on efficacy and safety in treatment-naïve patients.
Evaxion Biotech (NASDAQ: EVAX) has received Australian Therapeutic Goods Administration clearance to commence a Phase 2b trial for its patient-specific cancer immunotherapy EVX-01, in combination with Merck’s KEYTRUDA®. The trial aims to evaluate the safety and efficacy of this treatment in approximately 100 adults with unresectable or metastatic melanoma, focusing on overall response as the primary endpoint. The study is set to begin in Q2 2022, following promising data from the ongoing Phase 1/2a trial, where EVX-01 demonstrated a 67% benefit rate compared to 40% historical data for the anti-PD-1 therapy alone.
Evaxion Biotech A/S (NASDAQ: EVAX) has completed its follow-on public offering of 3,942,856 American Depositary Shares (ADSs) at a price of $7.00 per ADS. The offering included the full exercise of the underwriters’ option to purchase an additional 514,285 ADSs, generating approximately $27.6 million in gross proceeds before deductions. The ADSs are traded on the Nasdaq Capital Market. Oppenheimer & Co. Inc. served as the sole book-running manager for this offering, with additional support from Ladenburg Thalmann & Co. Inc. and Lake Street Capital Markets, LLC.
